nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

28.08.2023 | Research

STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer

verfasst von: Chengdong Huo, Yanmei Gu, Daijun Wang, Xiaoxia Zhang, Futian Tang, Bin Zhao, Tao Liu, Wenting He, Yumin Li

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 17/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tripartite motif-containing protein 21 (TRIM21) has E3 ubiquitin ligase activity and is involved in the regulation of various biological processes in vivo. TRIM21 has been found to have strong associations with various cancers. However, its role in gastric cancer is unclear.

Methods

The TCGA database was screened to obtain TRIM21 using WGCNA and PPI analyses. The TCGA database was used to evaluate the correlation of TRIM21 expression with patients’ clinical characteristics, prognosis, functional enrichment and immune cell infiltration. The role of TRIM21 in cell proliferation, apoptosis and invasion was verified by in vivo and in vitro assays. The UCSC and JASPAR databases were used to evaluate the regulatory role of STAT1 on TRIM21 transcription. Finally, dual-luciferase reporter assay was used to confirm the regulation of TRIM21 transcriptional activity by STAT1.

Results

As a key gene, high expression of TRIM21 inhibited the gastric cancer growth and was significantly enriched in apoptosis, cell proliferation, and JAK/STAT signaling pathways. TRIM21 expression was positively correlated with a variety of TICs, including T cells, NK cells, and DCs. In vivo assays, TRIM21 inhibited functions in gastric cancer cell lines, including inhibition of proliferation and migration, and promotion of apoptosis. Database analysis and dual-luciferase reporter assay showed that STAT1 inhibited the transcriptional activity of TRIM21. In vivo assays confirmed that TRIM21 inhibited tumor growth, and STAT1 expression was negatively correlated with STAT1.

Conclusion

TRIM21 is a tumor-suppressive gene in gastric cancer, and its transcriptional activity is inhibited by STAT1.

Nur mit Berechtigung zugänglich

Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS, Camargo MC (2018) The changing face of noncardia gastric cancer incidence among US non-hispanic whites. J Natl Cancer Inst 110(6):608–615. https://doi.org/10.1093/jnci/djx262CrossRefPubMedPubMedCentral

Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I (2020) Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut 69(5):823–829. https://doi.org/10.1136/gutjnl-2019-320234CrossRefPubMed

Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M (2018) NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol 11(1):83. https://doi.org/10.1186/s13045-018-0621-5CrossRefPubMedPubMedCentral

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC et al (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. https://doi.org/10.1016/j.immuni.2013.10.003CrossRefPubMed

Borlepawar A, Frey N, Rangrez AY (2019) A systematic view on E3 ligase Ring TRIMmers with a focus on cardiac function and disease. Trends Cardiovasc Med 29(1):1–8. https://doi.org/10.1016/j.tcm.2018.05.007CrossRefPubMed

Brauner S, Zhou W, Backlin C, Green TM, Folkersen L, Ivanchenko M et al (2015) Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J Intern Med 278(3):323–332. https://doi.org/10.1111/joim.12375CrossRefPubMed

Brauner S, Jiang X, Thorlacius GE, Lundberg AM, Östberg T, Yan ZQ et al (2018) Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content. Cardiovasc Res 114(1):158–167. https://doi.org/10.1093/cvr/cvx181CrossRefPubMed

Chen P, Tao L, Wang T, Zhang J, He A, Lam KH et al (2018) Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. Science 360(6389):664–669. https://doi.org/10.1126/science.aar1999CrossRefPubMedPubMedCentral

Crawford LJ, Johnston CK, Irvine AE (2018) TRIM proteins in blood cancers. J Cell Commun Signal 12(1):21–29. https://doi.org/10.1007/s12079-017-0423-5CrossRefPubMed

Du S, Liew SS, Zhang CW, Du W, Lang W, Yao CCY et al (2020) Cell-permeant bioadaptors for cytosolic delivery of native antibodies: a “Mix-and-Go” approach. ACS Cent Sci 6(12):2362–2376. https://doi.org/10.1021/acscentsci.0c01379CrossRefPubMedPubMedCentral

Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT (2019) TRIM21-from intracellular immunity to therapy. Front Immunol 10:2049. https://doi.org/10.3389/fimmu.2019.02049CrossRefPubMedPubMedCentral

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39. https://doi.org/10.1016/s0140-6736(13)61719-5CrossRefPubMed

Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M et al (2020) regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38(18):2053–2061. https://doi.org/10.1200/jco.19.03296CrossRefPubMed

Hatakeyama S (2017) TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 42(4):297–311. https://doi.org/10.1016/j.tibs.2017.01.002CrossRefPubMed

Heer EV, Harper AS, Sung H, Jemal A, Fidler-Benaoudia MM (2020) Emerging cancer incidence trends in Canada: the growing burden of young adult cancers. Cancer 126(20):4553–4562. https://doi.org/10.1002/cncr.33050CrossRefPubMed

Hou Y, Li X, Li Q, Xu J, Yang H, Xue M et al (2018) STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation. J Cell Mol Med 22(12):6077–6086. https://doi.org/10.1111/jcmm.13882CrossRefPubMedPubMedCentral

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY et al (2018) Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8(1):49–58. https://doi.org/10.1158/2159-8290.Cd-17-0787CrossRefPubMed

Jones EL, Laidlaw SM, Dustin LB (2021) TRIM21/Ro52—roles in innate immunity and autoimmune disease. Front Immunol 12:738473. https://doi.org/10.3389/fimmu.2021.738473CrossRefPubMedPubMedCentral

Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S et al (2020) Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol 21(8):1057–1065. https://doi.org/10.1016/s1470-2045(20)30271-0CrossRefPubMed

Kunishita Y, Yoshimi R, Kamiyama R, Kishimoto D, Yoshida K, Hashimoto E et al (2020) TRIM21 dysfunction enhances aberrant B-cell differentiation in autoimmune pathogenesis. Front Immunol 11:98. https://doi.org/10.3389/fimmu.2020.00098CrossRefPubMedPubMedCentral

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT et al (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906. https://doi.org/10.1016/j.cell.2009.10.027CrossRefPubMedPubMedCentral

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9CrossRefPubMed

Mondaca S, Janjigian YY (2019) Application of positron emission tomography imaging to personalize esophagogastric cancer care. Cancer 125(8):1214–1217. https://doi.org/10.1002/cncr.31940CrossRefPubMed

Nguyen JQ, Irby RB (2017) TRIM21 is a novel regulator of Par-4 in colon and pancreatic cancer cells. Cancer Biol Ther 18(1):16–25. https://doi.org/10.1080/15384047.2016.1252880CrossRefPubMed

Ping M, Wang S, Guo Y, Jia J (2022) TRIM21 improves apatinib treatment in gastric cancer through suppressing EZH1 stability. Biochem Biophys Res Commun 586:177–184. https://doi.org/10.1016/j.bbrc.2021.07.040CrossRefPubMed

Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y (2019) MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis 10(5):333. https://doi.org/10.1038/s41419-019-1530-4CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Tian X, Guan W, Zhang L, Sun W, Zhou D, Lin Q et al (2018) Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer. J Exp Clin Cancer Res 37(1):103. https://doi.org/10.1186/s13046-018-0773-8CrossRefPubMedPubMedCentral

Venuto S, Merla G (2019) E3 ubiquitin ligase TRIM proteins cells cell cycle and mitosis. Cells. https://doi.org/10.3390/cells8050510CrossRefPubMedPubMedCentral

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235. https://doi.org/10.1016/s1470-2045(14)70420-6CrossRefPubMed

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. https://doi.org/10.1038/ncomms3612CrossRefPubMed

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809. https://doi.org/10.1038/nrc2734CrossRefPubMedPubMedCentral

Zhang J, Wang F, Liu F, Xu G (2020) Predicting STAT1 as a prognostic marker in patients with solid cancer. Ther Adv Med Oncol 12:1758835920917558. https://doi.org/10.1177/1758835920917558CrossRefPubMedPubMedCentral

Zhang T, Wang B, Su F, Gu B, Xiang L, Gao L et al (2022) TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. Int J Biol Sci 18(11):4560–4577. https://doi.org/10.7150/ijbs.69933CrossRefPubMedPubMedCentral

Titel: STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer
verfasst von: Chengdong Huo
Yanmei Gu
Daijun Wang
Xiaoxia Zhang
Futian Tang
Bin Zhao
Tao Liu
Wenting He
Yumin Li
Publikationsdatum: 28.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 17/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05307-8

Springer Medizin

STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer